Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study.

ABSTRACT:

Introduction

Smoking is a strong risk factor for disease severity in Crohn's disease (CD) and cessation improves outcomes. The nicotine metabolite ratio (NMR) predicts cessation success with pharmacotherapy: varenicline doubles cessation over nicotine replacement therapy (NRT) for "normal", but not "slow" metabolizers. Varenicline side effects are heightened in slow metabolizers. Methods using NMR to optimize cessation pharmacotherapy have not been evaluated in CD.

Aims

We aim to determine the prevalence of smoking in a CD population and then assess these smokers' attitudes toward a personalized metabolism-informed care (MIC) approach to cessation.

Methods

In this observational study, we surveyed 1098 patients visiting an inflammatory bowel disease center about their

SUBMITTER: Scoville EA 

PROVIDER: S-EPMC7098646 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature